|
|
|
|
|
FREMONT, CA, 2023年3月28日 - (亞太商訊) - Q'Apel Medical Inc. was granted the CE Mark under MDR for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in treating patients suffering an acute ischemic stroke. The Walrus BGC has been utilized by Neuro Interventional physicians since 2019 and has successfully treated over 20,000 patients in the United States.
The Walrus BGC is a unique development in the field of Mechanical Thrombectomy procedures. It provides physicians with not only the known benefits of BGC use clinically, but unique to Walrus, superior ease of use in preparation in these urgent procedures. Importantly, Walrus enables the physicians to navigate the catheter into a more distal location easily and safely compared to other systems, which is associated with improved patient outcomes from stroke.
"The anticipation of Walrus in our international markets has been enormous, and we look forward to the same performance and loyalty around Walrus we have been fortunate to experience in the United States," said King Nelson, Q'Apel Medical's CEO.
"We are thrilled to be entering the EU and other international markets with Walrus and providing more physicians in more countries the unparalleled performance of our flagship catheter. This CE Mark certification represents a significant growth milestone for Q'Apel Medical providing access to new markets," commented Jodie Fam, Chief Marketing Officer & GM International.
About Q'Apel Medical
Q'Apel Medical designs highly innovative technologies for neurovascular interventions and unmet clinical needs. Q'Apel's portfolio comprises three products, the Walrus Balloon Catheter System, the Wahoo Hybrid Access System and Armadillo Radial Access System. Before Walrus came along, balloon-based variable stiffness catheters brought all manner of technological constraints. Not anymore. By blending flow control, trackability, support, and access into one revolutionary solution, Walrus offers truly unmatched functionality. The Wahoo Hybrid Access System and Armadillo Radial Access System are dual-mode catheters and part of the SelectFlex(TM) Family of Neurovascular Catheters. These devices feature two distinct operational modes, allowing physicians to easily switch modes at any point during a clinical case and reducing the need for multiple catheters in challenging procedures.
Media Contact:
Jodie Fam
415 244 9885
+44 7500702108
jfam@qapelmedical.com
info@qapelmedical.com
www.qapelmedical.com
Contact Information
Jodie Fam
Chief Marketing Officer & GM International
jfam@qapelmedical.com
4152449885
SOURCE: Q'Apel Medical Inc.
話題 Press release summary
部門 制药及生物技术, 健康与医药
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Seres delivers strong 2025 results, eyes path to become China's answer to Mercedes-Benz and BMW 
Apr 9, 2026, 09:42 HKT/SGT
|
|
|
Datavault AI Inc. (NASDAQ: DVLT) Announces $750 Million in Tokenization Contracts Signed in Q1 2026, Generating $77 Million in Associated Fees
Apr 9, 2026, 09:32 HKT/SGT
|
|
|
Stria Starts Strategic Transformation with Acquisition of First Gold Royalty
Apr 9, 2026, 07:29 HKT/SGT
|
|
|
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 2026
Apr 8, 2026, 23:15 HKT/SGT
|
|
|
Founders Metals Announces Increased Strategic Investment by Gold Fields
Apr 8, 2026, 22:29 HKT/SGT
|
|
|
Mobile Charging Industry Report: When "Piles" Start "Walking", Who Defines the New Rules of Energy Rescue?
Apr 8, 2026, 21:30 HKT/SGT
|
|
|
Military Metals Reports Maiden Inferred Resource Estimate Containing 67,000 Tonnes of Antimony and 222,000 Ounces of Gold at Flagship Trojarova Project, Europe
Apr 8, 2026, 21:29 HKT/SGT
|
|
|
Mitsubishi Motors Launches the Xforce in Malaysia
Wednesday, April 8, 2026 7:47:00 PM
|
|
|
Droid Investment Funds Launches 'The 10 Fund Competition Institutional Capital vs. The Wisdom of the Crowd'
Apr 8, 2026, 17:38 HKT/SGT
|
|
|
Guoyuan International: Essex Bio-Technology Embarks on Global Expansion, Maintains BUY Rating with Target Price of HK$6.84
Apr 8, 2026, 17:20 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
